Humanigen Inc (fka HGENQ)

[rstar]

https://roth.zoom.us/webinar/register/WN_FF_LgnOeQmm7VsRye97DtQ
ROTH Capital Healthcare Event - COVID-19 Therapeutics in Development - Oct 28, 2020 – 9:00 AM (ET) / 6:00 AM (PT)
Description
ROTH Capital Partners’ Jonathan Aschoff, Ph.D., Tony Butler, Ph.D., Scott Henry, CFA, Zegbeh Jallah, Ph.D., and Elemer Piros, Ph.D., of our Healthcare & Biotechnology team are hosting a webinar to discuss key therapies in the development to treat COVID disease. Our event takes place on October 28, 2020, starting at 9:00 am (ET). The therapies to be discussed are often overlooked and are beyond those of Gilead, Regeneron or Lilly.

There has been an intense focus on the development of COVID-19 vaccines. Several vaccines may emerge by year-end-2020/early-2021, yet the logistics of mass vaccination remain a concern. Additionally, vaccines may not be 100% effective, mutations could overcome vaccine generated immunity, and some people will opt out of vaccination. While herd immunity is critical to overcoming SARS sequelae, therapies against COVID-19 remain important. Minimizing hospitalization, amelioration of COVID-19 disease, and reducing deaths are important contributors to moving us all back into a society of “mask-less” normalcy.

Our Webinar includes three sessions:

Session 1. 9:00-10:20 am (ET). Immune Modulators to Ameliorate COVID Disease 1
INmune Bio (INMB)
Ampio Pharmaceuticals (AMPE)
Humanigen (HGEN)
aTyr Pharma (LIFE)
Omeros (OMER)